levofloxacin has been researched along with cyclizine in 4 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (cyclizine) | Trials (cyclizine) | Recent Studies (post-2010) (cyclizine) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 300 | 39 | 41 |
| Protein | Taxonomy | levofloxacin (IC50) | cyclizine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 1.021 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 1.158 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.852 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.633 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 1.551 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 6.2175 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.675 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.748 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 1.215 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.225 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 1.021 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.038 | |
| D(3) dopamine receptor | Homo sapiens (human) | 2.992 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.373 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.763 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
4 other study(ies) available for levofloxacin and cyclizine
| Article | Year |
|---|---|
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |